You are operating under a false assumption. The FDA doesn’t design the clinical trial. The sponsor is responsible for that. Then the sponsor submits the proposal to FDA for approval of the study plan before the trial can commence. In the phase 3 trial the dose and the number of doses and the amount of drug per dose would have already been established based on phase 1 and 2 results. The algorithm for making those decisions is also work done by sponsor, usually starting with animal studies before phase 1. Sounds to me like the sponsor simply wants to take another shot at showing an effect, using 4 doses instead of 2. If 2 doses was at least “safe” for the participants, FDA might allow it, but it requires a whole new proposal. And some new evidence to suggest 4 doses would be both safe and any better than 2. With a view to protecting the safety of participants, doesn’t that make sense? That’s the job of FDA.
Peter Lederman in Second Bout With COVID-19
I saw on Facebook late last night that Mike Fremer told one of his Audio Friends that he heard from Peter Lederman of Soundsmith that he is suffering his second round with COVID. Peter said he has blood clots on his lungs. That is all the post said. Here is hoping that Peter pulls through with a full recovery.
- ...
- 502 posts total
- 502 posts total